ELTX

AI Memo

Elicio Therapeutics

As of 2026-09-17/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-17 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

Q4 2026 ELI-002 7P combination-trial initiation • 2026-12-31

Base target: $2 / p=40% prob

Biggest risk

AMPLIFY-7P did not meet its primary endpoint, leaving the company reliant on subgroup analysis and early-stage combination strategies. Cash runway into Q1 2027 also implies a near-term financing or partnering requirement, making dilution and program-execution risk central to the thesis. [#PR-EARNINGS-2026-08-13]

Invalidation

Break below $1 or thesis failure.

What would change my mind?

The planned metastatic-pancreatic-cancer combination study and activated MSK-led neoadjuvant study preserve upside from ELI-002 7P. Reported complete responses following ELI-002 7P and subsequent checkpoint inhibition provide a rationale for further combination testing, but remain preliminary observations rather than controlled efficacy evidence. [#PR-EARNINGS-2026-08-13]

Research note

Recommendation

—

Confidence

medium

As of

2026-09-17

Base target

p=40%

Bull target

p=25%

Bear target

p=35%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Financing and runway checkpoint
MSK-led neoadjuvant Phase 1 execution
The planned metastatic-pancreatic-cancer combination study and activated MSK-led neoadjuvant study preserve upside from ELI-002 7P.

BearKey bullets

Low coverage and loose peer comparability make external valuation signals unreliable.
Stated cash runway extends only into Q1 2027 despite the July financing, creating material dilution, partnering, and development-continuity risk.
[#PR-EARNINGS-2026-08-13]

WatchKey bullets

Q4 2026 ELI-002 7P combination-trial initiation

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $2 (p=40%)

Target spread vs base: +133% / -63%

Scenario probabilities

Bull Target: $4 (p=25%)Base Target: $2 (p=40%)Bear Target: $1 (p=35%)

Commentary

Primary-source tone remains mixed-to-negative: new combination studies and preliminary response observations preserve optionality, but the failed Phase 2 primary endpoint and runway only into Q1 2027 dominate. The packet supplies no sufficient social coverage, verified options skew, short-interest figure, employee score, dependable analyst revisions, or post-event price-reaction attribution; zero values in the sentiment object denote unavailable inputs rather than neutral readings. The deterministic prior is negative across 5- to 120-day horizons, supporting cautious monitoring rather than a rebound thesis.

As of 2026-09-17 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Financing and runway checkpoint
MSK-led neoadjuvant Phase 1 execution

Scenarios

Bull Target (Scenario probability)

$4 / p=25% prob

Base Target (Scenario probability)

$2 / p=40% prob

Bear Target (Scenario probability)

$1 / p=35% prob

Analysis 2026-09-17 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.15

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
Q4 2026 ELI-002 7P combination-trial initiation
Elicio anticipates initiating a Phase 1 study of ELI-002 7P with a RAS small-molecule inhibitor, with or without anti-PD-1 therapy, in metastatic pancreatic cancer during Q4 2026. Initiation could restore clinical optionality after the Phase 2 primary-endpoint miss, but it would not provide efficacy validation. [#PR-EARNINGS-2026-08-13]
Prob 65.00% • Move 22.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

Financing and runway checkpoint
2027-03-31
The July 2026 $15 million financing supports stated runway only into Q1 2027. Absent partnering, reduced spending, or another source of capital, the approaching funding window creates material dilution and development-continuity risk. [#PR-EARNINGS-2026-08-13]
Prob 80% • Move -25% • Priced-in 60%

Long-term Catalysts

Months to a year

MSK-led neoadjuvant Phase 1 execution
2027-09-17
The Memorial Sloan Kettering-led Phase 1 study evaluating ELI-002 7P with chemotherapy and checkpoint inhibition has been activated. Enrollment progress and eventual clinical observations could validate the combination strategy, but no results timeline was disclosed. [#PR-EARNINGS-2026-08-13]
Prob 40% • Move 35% • Priced-in 20%

Risks

Low coverage and loose peer comparability make external valuation signals unreliable.
Stated cash runway extends only into Q1 2027 despite the July financing, creating material dilution, partnering, and development-continuity risk. [#PR-EARNINGS-2026-08-13]
The MSK-led neoadjuvant study has been activated, but the packet provides no enrollment, readout, or results timetable.
The Phase 2 AMPLIFY-7P trial did not meet its primary endpoint; subgroup findings may not support a viable Phase 3 strategy. [#PR-EARNINGS-2026-08-13]
The September 14 Form 8-K concerned the November 12 annual meeting and shareholder-proposal deadlines, not a new clinical or financing development. [#8-K-2026-09-14]
The planned metastatic combination program is Phase 1 and has not yet produced combination-study efficacy data.

Peers

Symbol	Summary
ACET	Similar-market-cap biotechnology candidate from the packet, useful only as a broad development-stage risk comparator; no shared indication, asset, or trial-stage evidence establishes it as a direct operating peer.
OKYO	Similar-market-cap biotechnology candidate, but the packet provides no evidence of comparable indications, clinical programs, or development timelines, limiting valuation relevance.
SERA	Same-sector, similar-market-cap candidate that illustrates small-cap life-sciences event risk, although direct product and clinical comparability are unsupported.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-17

Loading AI feed…

Symbol

Summary

ACET

Similar-market-cap biotechnology candidate from the packet, useful only as a broad development-stage risk comparator; no shared indication, asset, or trial-stage evidence establishes it as a direct operating peer.

OKYO

Similar-market-cap biotechnology candidate, but the packet provides no evidence of comparable indications, clinical programs, or development timelines, limiting valuation relevance.

SERA

Same-sector, similar-market-cap candidate that illustrates small-cap life-sciences event risk, although direct product and clinical comparability are unsupported.